Monogenic diabetes: A diagnostic algorithm for clinicians

Genes

Volumn 4, Issue 4, 2013, Pages 522-535

  Carroll, Richard W ^a,b   Murphy, Rinki ^c  

^a WELLINGTON HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Diabetes; Genetic testing; Maturity onset diabetes of the young; Monogenic; Neonatal diabetes

Indexed keywords

AUTOANTIBODY; C PEPTIDE; C REACTIVE PROTEIN; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 1BETA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HIGH DENSITY LIPOPROTEIN;

CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETOGENESIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; GCK GENE; GENE EXPRESSION REGULATION; GENETIC ALGORITHM; GENETIC SCREENING; HNF 1A GENE; HNF 1B GENE; HNF 4A GENE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MATERNALLY INHERITED DIABETES AND DEAFNESS; MONOGENIC DISORDER; MUTATIONAL ANALYSIS; NEWBORN DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHENOTYPIC VARIATION; RARE DISEASE; REVIEW; SENSITIVITY ANALYSIS;

EID: 84884881743     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes4040522     Document Type: Review

References (56)

1. Murphy, R.; Ellard, S.; Hattersley, A. Clinical implications of a molecular genetic classification of monogenic β-cell diabetes. Nat. Clin. Pract. Endoc. 2008, 4, 200-213.
2. Shields, B.M.; Hicks, S.; Shepherd, M.H.; Colclough, K.; Hattersley, A.T.; Ellard, S. Maturity-onset diabetes of the young (MODY): How many cases are we missing? Diabetologia 2010, 53, 2504-2508.
3. Hattersley, A.T.; Bruining, J.; Shield, J.; Njolstad, P.; Donaghue, K.C. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr. Diabetes 2009, 10, 33-42.
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012, 35, S64-S71.
5. Ellard, S.; Bellanne-Chantelot, C.; Hattersley, A.T. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008, 51, 546-553.
6. Vaxillaire, M.; Bonnefond, A.; Froguel, P. The lessons of early-onset monogenic diabetes for the understanding of diabetes pathogenesis. Clin. Pract. Endocrinol. Metab. 2012, 26, 171-187.
7. Temple, I.K.; Gardner, R.J.; Mackay, D.J.G.; Barber, J.C.K.; Robinson, D.O.; Shield, J.P.H. Transient neonatal diabetes: Widening the understanding of the etiopathogenesis of diabetes. Diabetes 2000, 49, 1359-1366.
8. Slingerland, A.S.; Shields, B.M.; Flanagan, S.E.; Bruining, G.J.; Noordam, K.; Gach, A.; Mlynarski, W.; Malecki, M.T.; Hattersley, A.T.; Ellard, S. Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births. Diabetologia 2009, 52, 1683-1685.
9. Gloyn, A.L.; Pearson, E.R.; Antcliff, J.F.; Proks, P.; Bruining, G.J.; Slingerland, A.S.; Howard, N.; Srinivasan, S.; Silva, J.M.C.L.; Molnes, J., et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 2004, 350, 1838-1849.
10. Babenko, A.P.; Polak, M.; Cave, H.; Busiah, K.; Czernichow, P.; Scharfmann, R.; Bryan, J.; Aguilar-Bryan, L.; Vaxillaire, M.; Frogue, P. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med. 2006, 355, 456-466.
11. Flanagan, S.E.; Patch, A.M.; Mackay, D.J.G.; Edghill, E.L.; Gloyn, A.L.; Robinson, D.; Shield, J.P.H.; Temple, I.K.; Ellard, S.; Hattersley, A.T. Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 2007, 56, 1930-1937.
12. Pearson, E.R.; Flechtner, I.; Njølstad, P.R.; Malecki, M.T.; Flanagan, S.E.; Larkin, B.; Ashcroft, F.M.; Klimes, I.; Codner, E.; Iotova, V., et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med. 2006, 355, 467-477.
13. Hattersley, A.T.; Ashcrolt, F.M. Activating mutations in Kir6.2 and neonatal diabetes: New clinical syndromes, new scientific insights, and new therapy. Diabetes 2005, 54, 2503-2513.
14. Slingerland, A.S.; Hurkx, W.; Noordamet, K.; Flanagan, S.E.; Jukema, J.W.; Meiners, L.C.; Bruining, G.J.; Hattersley, A.T.; Hadders-Algra, M. Sulphonylurea therapy improves cognition in a patient with theV59M KCNJ11 mutation. Diabetic Med. 2008, 25, 277-281.
15. Slingerland, A.S.; Nuboer, R.; Hadders-Algra, M.; Hattersley, A.T.; Bruining, G.J. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in apatient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 2006, 49, 2559-2563.
16. Boesgaard, T.R.; Pruhova, S.; Andersson, E.A.; Cinek, O.; Obermannova, B.; Lauenborg, J.; Damm, P.; Bergholdt, R.; Pociot, F.; Pisinger, C., et al. Further evidence that mutations in INS can be a rare cause of Maturity-Onset Diabetes of the Young (MODY). BMC Med. Genet. 2010, doi:10.1186/1471-2350-11-42.
17. Molven, A.; Ringdal, M.; Nordbø, A.M.; Ræder, H.; Støy, J.; Lipkind, G.M.; Steiner, D.F.; Philipson, L.H.; Bergmann, I.; Aarskog, D., et al. Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes 2008, 57, 1131-1135.
18. Ashcroft, F.M.; Rorsman, P. Diabetes mellitus and the β cell: The last ten years. Cell 2012, 148, 1160-1171.
19. Matschinsky, F.M.; Randle, P.J. Evolution of the glucokinase glucose sensor paradigm for pancreatic beta cells. Diabetologia 1993, 36, 1215-1217.
20. Stride, A.; Vaxillaire, M.; Tuomi, T.; Barbetti, F.; Njølstad, P.R.; Hansen, T.; Costa, A.; Conget, I.; Pedersen, O.; Søvik, O., et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 2002, 45, 427-435.
21. Velho, G.; Blanche, H.; Vaxillaire, M.; Bellanne-Chantelot, C.; Pardini, V.C.; Timsit, J.; Passa, Ph.; Deschamp, I.; Robert, J.-J.; Weber, I.T., et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 1997, 40, 217-224.
22. Steele, A.M.; Wensley, K.J.; Ellard, E.; Murphy, R.; Shepherd, M.; Colclough, K.; Shields, B.M.; Hattersley, A.T. Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: Observational case control studies. PLoS One 2013, 8, e65326.
23. Njølstad, P.R.; Søvik, O.; Cuesta-Munoz, A.; Bjørkhaug, L.; Massa, O.; Barbetti, F.; Undlien, D.E.; Shiota, C.; Magnuson, M.A.; Molven, A., et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N. Engl. J. Med. 2001, 344, 1588-1592.
24. Njølstad, P.R.; Sagen, J.V.; Bjørkhaug, L.; Odili, S.; Shehadeh, N.; Bakry, D.; Sarici, S.M.; Alpay, F.; Molnes, J.; Molven, A., et al. Matschinsky. Permanent neonatal diabetes caused by glucokinase deficiency: Inborn error of the glucose-insulin signaling pathway. Diabetes 2003, 52, 2854-2860.
25. Murphy, R.; Tura, A.; Clark, P.M.; Holst, J.J.; Mari, A.; Hattersley, A.T. Glucokinase, the pancreatic glucose sensor, is not the gut glucose sensor. Diabetologia 2009, 52, 154-159.
26. Martin, D.; Bellanne-Chantelot, C.; Deschamps, I.; Froguel, P.; Robert, J.J.; Velho, G. Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2). Diabetes Care 2008, 31, 1321-1323.
27. Colomand, C.; Corcoy, R. Maturity onset diabetes of the young and pregnancy. Best Pract. Res. Clin. Endocrinol. Metab. 2010, 24, 605-615.
28. Ellard, S.; Beards, F.; Allen, L.I.S.; Shepherd, M.; Ballantyne, E.; Harvey, R.; Hattersley, A.T. A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria. Diabetologia 2000, 43, 250-253.
29. Spyer, G.; Hattersley, A.T.; Sykes, J.E.; Sturley, R.H.; MacLeod, K.M. Influence of maternal and fetal glucokinase mutations in gestational diabetes. Am. J. Obstet. Gynecol. 2001, 185, 240-241.
30. Chakera, A.J.; Carleton, V.L.; Ellard, S.; Wong, J.; Yue, D.K.; Pinner, J.; Hattersley, A.T.; Ross, G.P. Antenatal diagnosis of fetal genotype determines if maternal hyperglycaemia due to a glucokinase mutation requires treatment. Diabetes Care 2012, 35, 1832-1834.
31. Maestro, M.A.; Cardalda, C.; Boj, S.F.; Luco, R.F.; Servitja, J.M.; Ferrer, J. Distinct roles of HNF1beta, HNF1alpha, and HNF4alpha in regulating pancreas development, beta-cell function and growth. Endocr. Dev. 2007, 12, 33-45.
32. Fajans, S.S.; Bell, G.I.; Polonsky, K.S. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N. Eng. J. Med. 2001, 345, 971-980.
33. Stride, A.; Ellard, S.; Clark, P.; Shakespeare, L.; Salzmann, M.; Shepherd, M.; Hattersley, A.T. β-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1α mutation carriers. Diabetes Care 2005, 28, 1751-1756.
34. Kapoor, R.R.; Locke, J.; Colclough, K.; Wales, J.; Conn, J.J.; Hattersley, A.T.; Ellard, S.; Hussain, K. Persistent hyperinsulinemic hypoglycaemia and maturity-onset diabetes of the young due to heterozygous HNF4A mutations. Diabetes 2008, 57, 1659-1663.
35. Isomaa, B.; Henricsson, M.; Lehto, M.; Forsblom, C.; Karanko, S.; Sarelin, L.; Häggblom, M.; Groop, L. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 1998, 41, 467-473.
36. Edghill, E.L.; Bingham, C.; Ellard, S.; Hattersley, A.T. Mutations in hepatocyte nuclear factor-1β and their related phenotypes. J. Med. Genet. 2006, 43, 84-90.
37. Shepherd, M.; Shields, B.; Ellard, S.; Rubio-Cabezas, O.; Hattersley, A.T. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet. Med. 2009, 26, 437-441.
38. Shepherd, M.; Pearson, E.R.; Houghton, J.; Salt, G.; Ellard, S.; Hattersley, A.T. No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care. 2003, 26, 3191-3192.
39. Murphy, R.; Turnbull, D.M.; Walker, M.; Hattersley, A.T. Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation. Diabet. Med. 2008, 25, 383-399.
40. Maassen, J.A.; Janssen, G.M.C.; 'tHart, L.M. Molecular mechanisms of mitochondrial diabetes (MIDD). Ann. Med. 2005, 37, 213-221.
41. Guillausseau, P.-J.; Massin, P.; Dubois-LaForgue, D.; Timsit, J.; Virally, M.; Gin, H.; Bertin, E.; Blickle, J.-F.; Bouhanick, B.; Cahen, J., et al. Maternally inherited diabetes and deafness: A multicenter study. Ann. Intern. Med. 2001, 134, 721-728.
42. Dykens, J.A.; Jamieson, J.; Marroquin, L.; Nadanaciva, S.; Billis, P.A.; Will, Y. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human heptaocytes in vitro. Toxicol. Appl. Pharmacol. 2008, 233, 203-210.
43. Suzuki, S.; Hinokio, Y.; Ohtomo, M.; Hirai, M.; Hirai, A.; Chiba, M.; Kasuga, S.; Satoh, Y.; Akai, H.; Toyota, T. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetologia 1998, 41, 584-588.
44. Bowman, P.; Flanagan, S.E.; Edghill, E.L.; Damhuis, A.; Shepherd, M.H.; Paisey, R.; Hattersley, A.T.; Ellard, S. Heterozygous ABCC8 mutations are a cause of MODY. Diabetologia 2012, 55, 123-127.
45. Greeley, S.A.W.; John, P.R.; Winn, A.N.; Ornelas, J.; Lipton, R.B.; Philipson, L.H.; Bell, G.I.; Huang, E.S. The cost-effectiveness of personalized genetic medicine: The case of genetic testing in neonatal diabetes. Diabetes Care 2011, 34, 622-627.
46. Naylor, R.N.; John, P.R.; Winn, A.N.; Philipson, L.H.; Greeley, S.A.W.; Bell, G.I.; Huang, E.S. The Cost-Effectiveness of MODY Genetic Testing. Diabetes 2012, 61, A36.
47. Verge, C.F.; Howard, N.J.; Rowley, M.J.; Mackay, I.R.; Zimmet, P.Z.; Egan, M.; Hulinska, H.; Hulinsky, I.; Silvestrini, R.A.; Kamath, S., et al. Anti-glutamate decarboxylase and other antibodies at the onset of childhood IDDM: A population-based study. Diabetologia 1994, 37, 1113-1120.
48. Schober, E.; Rami, B.; Grabert, M.; Thon, A.; Kapellen, T.; Reinehr, T.; Holl, R.W. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: Experience from a large multicentre database. Diabet. Med. 2009, 26, 466-473.
49. Shields, B.M.; McDonald, T.J.; Ellard, S.; Campbell, M.J.; Hyde, C.; Hattersley, A.T. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia 2012, 55, 1265-1272.
50. Wang, L.; Lovejoy, N.F.; Faustman, D.L. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 2012, 35, 465-470.
51. Besser, R.E.; Shields, B.M.; Hammersley, S.E.; Colclough, K.; McDonald, T.J.; Gray, Z.; Heywood, J.J.; Barrett, T.G.; Hattersley, A.T. Home urine C-peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes. Pediatr. Diabetes 2013, 14, 181-188.
52. Wenzlau, J.M.; Juhl, K.; Yu, L.; Moua, O.; Sarkar, S.A.; Gottlieb, P.; Rewers, M.; Eisenbarth, G.S.; Jansen, J.; Davidson, H.W., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc. Natl. Acad. Sci. USA 2008, 104, 17040-17045.
53. McDonald, T.J.; Colclough, K.; Brown, R.; Shields, B.; Shepherd, M.; Bingley, P.; Williams, A.; Hattersley, A.T.; Ellard, S. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet. Med. 2011, 28, 1028-1033.
54. Owen, K.R.; Thanabalasingham, G.; James, T.J.; Karpe, F.; Farmer, A.J.; McCarthy, M.I.; Gloyn, A.L. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care 2010, 33, 1919-1924.
55. McDonald, T.J.; Shields, B.M.; Lawry, J.; Owen, K.R.; Gloyn, A.L.; Ellard, S.; Hattersley, A.T. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care 2011, 34, 1860-1862.
56. McDonald, T.J.; McEneny, J.; Pearson, E.R.; Thanabalasingham, G.; Szopa, M.; Shields, B.; Ellard, S.; Owen, K.R.; Malecki, M.T.; Hattersley, A.T., et al. Lipoprotein composition in HNF1A-MODY: Differentiating between HNF1A-MODY and type 2 diabetes. Clin. Chim. Acta 2012, 413, 927-932.